Compare EVO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | CMPX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 927.5M |
| IPO Year | N/A | 2020 |
| Metric | EVO | CMPX |
|---|---|---|
| Price | $2.73 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $14.57 |
| AVG Volume (30 Days) | 95.9K | ★ 12.2M |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $10.05 | $934.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $1.61 |
| 52 Week High | $4.80 | $6.88 |
| Indicator | EVO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 26.23 |
| Support Level | $2.32 | $1.61 |
| Resistance Level | $3.78 | $3.54 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 19.16 | 46.05 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.